Name | RIPK1-IN-7 |
Description | RIPK1-IN-7 is a potent and selective inhibitor of RIPK1 (Kd of 4 nM and enzymatic IC50 of 11 nM), exhibiting excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model. |
In vitro | In the TSZ-induced HT29 cell necroptosis model, RIPK1-IN-7 shows potent cell protection effect (EC50 of 2nM). RIPK1-IN-7 displays considerable activity against several other kinases(Flt4, TrkA, TrkB, TrkC, Axl, HRI, Mer, and MAP4K5 with IC50s of 20, 26, 8, 7, 35, 26, 29, and 27 nM, respectively). |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 60 mg/mL (124.62 mM), Sonication is recommended. H2O : 0.1 mg/mL (insoluble)
|
Keywords | TrkC | TrkB | TrkA | RIPK1-IN-7 | RIPK-1-IN-7 | RIPK1IN7 | RIPK1 IN 7 | RIPK | RIP kinase | Receptor-interacting protein kinases | Mer | Inhibitor | inhibit | HRI | Flt4 | Axl |
Inhibitors Related | PK68 | Necrostatin-1 | RIPK2-IN-5 | Oditrasertib | LY-364947 | Necroptosis-IN-1 | ICCB-19 hydrochloride | RIPK1-IN-9 | Necrostatin-34 | RIPA-56 | GSK2983559 free acid | Zharp2-1 |
Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | NO PAINS Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Liver Cancer Compound Library |